MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 140 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222).
Ravi Ramjeesingh, Janarthanan Kankesan, Bingshu E. Chen, Joseph L. Pater, Lei Han, Patti O’Brien +3 more
2015· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Pre-admission escalation rate of daily opioid consumption (PERDOC), and total morphine equivalent daily dose on the first complete day of admission (D1-MEDD) to a tertiary-level palliative care unit (TPCU): Correlates and predictors in patients with advan
Peter G. Lawlor, Cheryl Nekolaichuk, Sue Lowe, Alan Kelly, Robin L. Fainsinger, Sharon Watanabe +1 more
2007· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
In Reply:
Bruno Gagnon, Nancy E. Mayo
2005· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · insufficient_payloadconsensus · none
0
citations
aboutno affunlabeled
Small bowel adenocarcinoma and associated malignancies
Shaheen Ahmed, Ruqaiya Shahid, Adnan Sami, Imad Ahmad, Subhash Yadav, D. Mirchandani +2 more
2005· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affaboutunlabeled
A value framework analysis of the Canadian Cancer Trials Group.
Joseph C. Del Paggio, Adam Fundytus, Wilma M. Hopman, Joseph L. Pater, Bingshu E. Chen, Michael Brundage +2 more
2018· article· en· Journal of Clinical Oncology· Economics, Econometrics and Finance
machine prediction:candidate · metaresearchconsensus · metaresearch
0
citations

How this was built: Screen · Findings · About